Investing.com -- Tempus AI, Inc. (NASDAQ:TEM) stock rose 5% on Monday after the company announced it received 510 (k) clearance from the U.S. Food and Drug Administration for its RNA-based Tempus xR ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

The world of cells is surprisingly noisy. Each cell carries unique genetic information, but when we try to measure cellular ...

Alcohol doesn’t just damage the liver — it locks its cells in a strange “in-between” state that prevents them from healing.

Tempus AI Inc. shares rose after it said it received 510 (k) clearance from the Food and Drug Administration for its RNA-based in vitro diagnostic device. Its stock recently rose 5.2% to $92.85 in ...

RNA is central to how cells function. Through the detailed study of RNA that combines molecular biology with advanced ...

Through a comprehensive approach combining transcriptomic profiling, histological analysis, and functional validation in ...

Gastric cancer remains one of the world’s leading causes of cancer deaths, yet the molecular steps driving its onset remain ...

The world of cells is surprisingly noisy. Each cell carries unique genetic information, but when we try to measure cellular ...

Gastric cancer often develops through a gradual sequence of changes, beginning with superficial gastritis and advancing ...

Researchers found that by combining immunotherapy with the drug indisulam, they could achieve a complete therapeutic response ...